| 药品通用名/英文 |
NDC号/批准号 |
商标名 |
成份名 |
剂型 |
公司/生产厂 |
上市国/产地 |
规格/包装规格 |
备注 |
操作 |
| 纳武利尤单抗注射液 |
|
OPDIVO |
nivolumab. |
injection |
Bristol-Myers Squibb Pharma EEIG |
Netherland/Ierland |
100mg/10ml/bottle |
|
请先登录 |
| 纳武利尤单抗注射液 |
|
OPDIVO |
nivolumab. |
injection |
Bristol-Myers Squibb Pharma EEIG |
Netherland/Ierland |
240mg/24ml/bottle |
|
请先登录 |
| 芦卡帕利片 |
|
Rubraca |
rucaparib |
tablets |
Almac Pharma Services Limited/Almac Pharma Services (Ireland) Ltd |
UK/Ireland |
200mg/60tablet/bottle |
|
请先登录 |
| 芦卡帕利片 |
|
Rubraca |
rucaparib |
tablets |
Almac Pharma Services Limited/Almac Pharma Services (Ireland) Ltd |
UK/Ireland |
250mg/60tablet/bottle |
|
请先登录 |
| 芦卡帕利片 |
|
Rubraca |
rucaparib |
tablets |
Almac Pharma Services Limited/Almac Pharma Services (Ireland) Ltd |
UK/Ireland |
300mg/60tablet/bottle |
|
请先登录 |
| 芦卡帕利片 |
69660-201-91 |
RUBRACA |
rucaparib |
tablet |
Clovis Oncology, Inc |
USA |
200mg/60tablet/bottle |
|
请先登录 |
| 芦卡帕利片 |
69660-202-91 |
RUBRACA |
rucaparib |
tablet |
Clovis Oncology, Inc |
USA |
250mg/60tablet/bottle |
|
请先登录 |
| 芦卡帕利片 |
69660-203-91 |
RUBRACA |
rucaparib |
tablet |
Clovis Oncology, Inc |
USA |
300mg/60tablet/bottle |
|
请先登录 |
| 芦卡帕利片 |
|
RUBRACA |
rucaparib |
tablet |
Clovis Oncology Ireland Ltd./Almac Pharma Services Limited |
Italy / UK |
200mg/60tablet/bottle |
|
请先登录 |
| 芦卡帕利片 |
|
RUBRACA |
rucaparib |
tablet |
Clovis Oncology Ireland Ltd./Almac Pharma Services Limited |
Italy / UK |
250mg/60tablet/bottle |
|
请先登录 |
| 芦卡帕利片 |
|
RUBRACA |
rucaparib |
tablet |
Clovis Oncology Ireland Ltd./Almac Pharma Services Limited |
Italy / UK |
300mg/60tablet/bottle |
|
请先登录 |
| 芦卡帕利片 |
|
RUBRACA |
rucaparib |
tablet |
Clovis Oncology Ireland Ltd. |
Netherland/Ierland |
200mg/60tablet/bottle |
|
请先登录 |
| 芦卡帕利片 |
|
RUBRACA |
rucaparib |
tablet |
Clovis Oncology Ireland Ltd. |
Netherland/Ierland |
250mg/60tablet/bottle |
|
请先登录 |
| 芦卡帕利片 |
|
RUBRACA |
rucaparib |
tablet |
Clovis Oncology Ireland Ltd. |
Netherland/Ierland |
300mg/60tablet/bottle |
|
请先登录 |
| 阿替利组单抗注射剂 |
|
TECENTRIQ |
Atezolizumab |
Injection |
中外製薬株式会社 |
JP |
840mg/14mL/bottle |
|
请先登录 |
| 阿替利组单抗注射剂 |
|
TECENTRIQ |
Atezolizumab |
Injection |
中外製薬株式会社 |
JP |
1200mg/20mL/bottle |
|
请先登录 |
| 阿替利组单抗注射剂 |
50242-918-01 |
TECENTRIQ |
atezolizumab |
injection |
Genentech, Inc. |
USA |
840mg/14mL/bottle |
|
请先登录 |
| 阿替利组单抗注射剂 |
50242-917-01 |
TECENTRIQ |
atezolizumab |
injection |
Genentech, Inc. |
USA |
1200mg/20mL/bottle |
|
请先登录 |
| 阿替利组单抗注射剂 |
|
Tecentriq |
atezolizumab |
injection |
Roche Pharma AG |
UK/Germany |
840mg/14mL/bottle |
|
请先登录 |
| 阿替利组单抗注射剂 |
|
Tecentriq |
atezolizumab |
injection |
Roche Pharma AG |
UK/Germany |
1200mg/20mL/bottle |
|
请先登录 |
| 阿替利组单抗注射剂 |
|
Tecentriq |
atezolizumab |
injection |
Roche Registration GmbH |
France/Germany |
840mg/14mL/bottle |
|
请先登录 |
| 阿替利组单抗注射剂 |
|
Tecentriq |
atezolizumab |
injection |
Roche Registration GmbH |
France/Germany |
1680mg/28mL/bottle |
|
请先登录 |
| 阿替利组单抗注射剂 |
|
Tecentriq |
atezolizumab |
injection |
Roche Registration GmbH |
Italy / Germania |
840mg/14mL/bottle |
|
请先登录 |
| 阿替利组单抗注射剂 |
|
Tecentriq |
atezolizumab |
injection |
Roche Registration GmbH |
Italy / Germania |
1680mg/28mL/bottle |
|
请先登录 |
| 阿替利组单抗注射剂 |
|
Tecentriq |
atezolizumab |
injection |
Roche Registration GmbH |
Netherland/Germany |
840mg/14mL/bottle |
|
请先登录 |
| 阿替利组单抗注射剂 |
|
Tecentriq |
atezolizumab |
injection |
Roche Registration GmbH |
Netherland/Germany |
1680mg/28mL/bottle |
|
请先登录 |
| 维奈克拉片 |
0074-0561-14 |
VENCLEXTA |
venetoclax |
tablet |
AbbVie Inc. |
USA |
10 mg /14 *10/tablets/box |
|
请先登录 |
| 维奈克拉片 |
0074-0566-07 |
VENCLEXTA |
venetoclax |
tablet |
AbbVie Inc. |
USA |
50 mg /7 *50/tablets/box |
|
请先登录 |
| 维奈克拉片 |
0074-0561-11 |
VENCLEXTA |
venetoclax |
tablet |
AbbVie Inc. |
USA |
10 mg/2*10/tablets/box |
|
请先登录 |
| 维奈克拉片 |
0074-0566-11 |
VENCLEXTA |
venetoclax |
tablet |
AbbVie Inc. |
USA |
50 mg/1*50/tablet/box |
|
请先登录 |
400-8577-888